Relieves symptoms associated with oral inflammatory lesions and ulcerative lesions…. ANDA 40771, held by Rising. Triamcinolone Acetonide.
As of Nov 15, 2026, ANDA 40771 (Triamcinolone Acetonide), held by Rising, was first approved by FDA on Jul 1, 2010, with 2 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Triamcinolone Acetonide Dental Paste USP, 0.1% is indicated for adjunctive treatment and for the temporary relief of symptoms associated with oral inflammatory lesions and ulcerative lesions resulting from trauma.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 1, 2010 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Triamcinolone Acetonide0.1% · paste;dental | Triamcinolone Acetonide | Rx |
| Nov 4, 2022 | Supplement 2Labeling · Standard review | Approved | None posted |
| Aug 2, 2011 | Supplement 1Labeling | Approved | None posted |
| Jul 1, 2010 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
